Online inquiry

IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-G4h-28-F9Z-TpERt CAR(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ7223MR)

This product GTTS-WQ7223MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD19 gene. The antibody can be applied in Diffuse Large B Cell Lymphoma (DLBCL) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001178098.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 930
UniProt ID P15391
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-G4h-28-F9Z-TpERt CAR(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ7223MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4952MR IVTScrip™ mRNA-Anti-GP, c13C6-FR1-N(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA c13C6-FR1-N
GTTS-WQ12490MR IVTScrip™ mRNA-Anti-IL20, NN-8226(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA NN-8226
GTTS-WQ1059MR IVTScrip™ mRNA-Anti-TNFRSF10B, ABBV-621(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ABBV-621
GTTS-WQ5209MR IVTScrip™ mRNA-Anti-CD22, CAT-8015(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA CAT-8015
GTTS-WQ13338MR IVTScrip™ mRNA-Anti-PDCD1, PF-06801591(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA PF-06801591
GTTS-WQ3815MR IVTScrip™ mRNA-Anti-NCAM1, BB-10901(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BB-10901
GTTS-WQ7552MR IVTScrip™ mRNA-Anti-GPC3, GC33(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA GC33
GTTS-WQ3718MR IVTScrip™ mRNA-Anti-MSLN, BAY 94-9343(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BAY 94-9343
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW